Tag Archives: specialty pharma

Specialty Drugs and Reimbursement

By Ben Comer | Published: January 21, 2013
To maximize return on investment, pharma must think strategically about reimbursement channels and how new specialty products will perform in one versus another. By 2018, the amount health insurers spend per person on specialty, or biologic drugs, will equal or surpass the amount spent on traditional products, according to a new report. With the emergence [...]
Posted in Biotech, Strategy | Also tagged , , | Leave a comment

Generics Win in an Express Scripts/Medco deal

By Ben Comer | Published: July 27, 2011
As a preferred generics supplier to Medco’s mail-order business, Novartis’ Sandoz division, for one, should be waiting with bated breath – and champagne at the ready – for an FTC approval of Express Scripts’ proposed $29.1 billion acquisition of Medco, which would combine two of the three largest pharmacy benefits managers (PBM), according to industry [...]
Posted in Deals, Strategy, pricing | Also tagged , , , , , | 4 Comments

With Cephalon Buy, Teva Bets on Brand Drugs and More In-House Innovation

By Ben Comer | Published: May 4, 2011
If commodity generics and in-licensing deals are all the rage, then Teva just strapped on a fanny pack with its $6.8 billion acquisition of Cephalon. The deal is expected to skyrocket Teva’s brand drug portfolio to $7 billion in annual sales, making Teva “not only the world’s largest generics company, but also one of the world’s [...]
Posted in Deals, Strategy | Also tagged , , , | 3 Comments